For 10-year-old Brynlee Clevenger, it was the possibility of helping other kids with type 1 diabetes (T1D) that prompted her to join a clinical trial.

TrialNet’s latest clinical study will test two established immune therapies—rituximab-pvvr followed by abatacept—to see if the combination can preserve insulin production in people recently diagnosed with type 1 diabetes (T1D).